ClinicalTrials.gg
Active, not recruitingNCT00582296Updated Jan 7, 2026

Multi-Organ Screening Recommendations in Patients With Lynch Syndrome

An observational study in Lynch Syndrome, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,530
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States — 21 open to participants now, 33 under way, 2 of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · United States.

Enrollment
4th of 29
1,530 · median 300
Started
2004
the only one that year
Observational
29 of 72
8 open now
Primary completion
2026-12
later than 6 of 32 live
Registered
6th of 72
by date
Lead sponsor
2 of 72
Memorial Sloan Kettering Cancer Center

Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, this one is the 4th largest by enrollment of the 29 observational ones that give a count, is the only one that started in 2004, is one of 29 observational ones, reaches primary completion later than 6 of the 32 other live ones, and was the 6th registered.

Colorectal Neoplasms, Hereditary Nonpolyposis

147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 61 are open to participants now.

Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →

Open to participants now

21 of the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to examine how people with a family history of colon cancer and other related cancers respond to recommendations for cancer screening after genetic counseling. The purpose of your participation would be to help us learn more about whether people with a personal and/or family history of colorectal cancer and other cancers follow cancer screening recommendations.

03

Conditions studied

  • Lynch Syndrome

Keywords

  • Lynch syndrome
  • 04-144
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients seeking genetic counseling with or without genetic testing for colorectal cancer risk and/or suspected Lynch Syndrome will be recruited and offered enrollment during their first counseling visit at the Clinical Genetics Service at MSKCC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A patient will be eligible for enrollment if he/she is self-referred or physician-referred for genetic counseling at Memorial Sloan-Kettering Cancer Center's (MSKCC) Clinical Genetics Service due to a concern about increased risk for colon cancer or;
  • An individual who presents for genetic counseling at MSKCC's Clinical Genetics Service after undergoing genetic testing at an outside institution with a documented mutation in any gene associated with Lynch Syndrome or;
  • An individual who in the context of genetic counseling has received stricter colorectal and/or gynecologic screening recommendations than that of the general population regardless of genetic test results.
  • DNA of patients who have been consented to protocol 93-102 ("Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers"), who meet the eligibility criteria listed above, will also be eligible for inclusion in this study.

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded from this study if: he/she has physical, cognitive or psychiatric conditions that interfere with ability to give meaningful ; he/she cannot read, write or communicate in English; he/she is less than 18 years of age; he/she has received a diagnosis of FAP.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,530 participants (actual)
Patient registry
No

Groups and cohorts

  • 1

    multi-organ follow-up

    Behavioral: questionnaires, telephone interview, optional blood drawn

  • 2

    control follow-up

    Behavioral: questionnaires, telephone interview and optional blood drawn

Interventions

  • Behavioralquestionnaires, telephone interview, optional blood drawn

    Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).

  • Behavioralquestionnaires, telephone interview and optional blood drawn

    Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).

06

What researchers measure

Primary outcomes

  1. To assess adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations in patients with Lynch Syndrome.

    Time frame: conclusion of study

Secondary outcomes

  1. To evaluate predictive factors for adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations.

    Time frame: conclusion of study

07

Study locations

8 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2004 (actual). Primary completion is estimated for Dec 2026, 264 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Dec 28, 2007
StartActual
Dec 2004
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00582296
Responsible party
Sponsor
First posted
Dec 28, 2007
Start date
Dec 2004
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Zsofia Stadler, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion